2025年 · 第105卷第38期

Stroke is one of the leading causes of death and disability among residents worldwide, among which ischemic stroke (i.e. cerebral infarction) is the most common type. Effectively reducing the disability rate and mortality rate of cerebral infarction is the core goal of stroke prevention and treatment. Patients with cerebral infarction can present with severe neurological deficit. Severe cerebral infarction is difficult to treat and has poor prognosis. Previous studies often exclude it, and related studies are obviously lagging behind, and baseline data are lacking.

Professor Wang Yingde's team from the Department of Gastroenterology, the First Affiliated Hospital of Dalian Medical University recently completed a basic study focusing on how FMS-like tyrosine kinase 3 ligand (FLT3L) promotes the mechanism of regulatory dendritic cells (DCreg) -induced regulatory T cells (Treg) expansion. Intestinal immune homeostasis is essential for health, and DCreg is a subset of dendritic cells in gut-associated lymphoid tissue (GALT) with a unique ability to induce immune tolerance, whose dysfunction is closely related to inflammatory bowel diseases (IBD) such as ulcerative colitis (UC). Clarifying how FLT3L regulates DCreg function and Treg amplification is of great significance for understanding the mechanism of intestinal immune tolerance and developing DCREG-based cell therapies.

Vascular disease is one of the leading causes of death among Chinese residents, accounting for more than 40% of the total death toll, and exploring adjustable dietary factors is crucial for its prevention. Previous related studies were mostly based on European populations or small domestic samples, and the conclusions were difficult to directly apply to Chinese populations. This study filled this gap.

Article "Guidelines for the Diagnosis and Treatment of Insomnia (2025 Edition), Volume 105, Issue 34, September 9, 2025, page 2975, top left corner" 2. Medication: Recommended as a first-line treatment option for insomnia in children and used only when behavioral therapy is ineffective or sleep problems are persistent and severe. "It should read" 2. Medication: Not recommended as a first-line treatment option for insomnia in children and used only when behavioral therapy is ineffective or sleep problems are persistent and severe. "It is hereby corrected.